Partners for the last four years, Biocodex became a shareholder and board member of TargEDys in 2019, and shortly after became the distributor of TargEDys’ Symbiosys Satylia ingredient in France, Portugal and Poland.
Now, the healthcare firm has acquired 100% of TargEDys’ shares, to consolidate the group’s "strong ambition" in the microbiome and accelerate TargEDys’ development globally.
The partners say the acquisition will be mutually beneficial.
Aurore Matton, general manager of TargEDys, says: “This integration within Biocodex will be an enabler of TargEDys’ mission to bring the microbiome to the heart of healthcare, and increase awareness on its unique strains portfolio with scientifically proven efficacy”.
Symbiosys Satylia is a precision probiotic supplement based on Hafnia alvei HA4597 with a characterised mechanism of action at the molecular level: it increases the feeling of fullness thanks to the ability of the protein ClpB to mimic the satiety hormone alpha-MSH.
Its efficacy was demonstrated in a clinical trial involving 230 overweight adults. It is a new, natural, safe, and effective solution to weight management and a multi-award winner – including Best Probiotic of the Year in the 2021 NutraIngredients Awards.
Nicolas Coudurier, chief executive officer of Biocodex, adds: “With the acquisition of TargEDys, we strengthen our ambition to become the leader in Microbiota care. We are happy to welcome a like-minded team with the common drive of improving the health and well-being of women and men worldwide through microbiome-based innovations and education.”
From Probiotics to PreciBiomics
TargEDys is a commercial-stage French biotech company specialising in the development of nutraceutical solutions for the control of appetite through microbiome interventions.
The company is the result of more than 15 years of research on the microbiota, conducted within academic laboratories.
The team first developed and started the commercialisation of a product based on the "PreciBiomic" - aka precision probiotic - strain Hafnia alvei HA4597 which has been clinically demonstrated to have efficacy in weight and appetite.
TargEDys develops a product portfolio focusing on overweight, undernutrition and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies.
About Biocodex
Founded in 1953, Biocodex developed the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745.
Today, the firm focuses on three main areas of business: Microbiota care, Women’s health, and Orphan diseases.
With more than 1,600 employees, the business generated net revenues of more than €500 million in 2022, including 35% in France and 65% internationally. The group is present in 115 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.